Latest & greatest articles for Severe Persistent Asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Severe Persistent Asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Severe Persistent Asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Severe Persistent Asthma

1. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Bronchial thermoplasty (...) for the treatment of severe persistent asthma. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1384. 2015 Authors' objectives Bronchial thermoplasty (BT) is performed in a bronchoscopy/endoscopy suite and takes about an hour to complete each of the three required treatments. BT is usually conducted under moderate sedation. Post-procedure, patients are observed and monitored for approximately 2-4 hours. Authors' conclusions After considering the available evidence presented in relation

2015 Health Technology Assessment (HTA) Database.

2. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Appl Applic Date o Context at www 1. An Ass thermop Departm 2. After co and cos for BT populat effectiv 3. MSAC severe a is defin combin procedu airways broncho compris The pat severe a that con lication N cant: of MSAC c t for decisio w.msac.gov. Purpose o essment Re plasty (BT) ment of Hea MSAC’s a onsidering t st-effectiven for the treat tion, its plac veness and r Summary noted that t asthma desp ned as the m ned with a lo (...) ure involvin s through a oscope unde ses three pro tient popula asthma who nfirmation r Pub No. 1384 s onsiderat on: MSAC m au of applica eport reques for severe p alth in Octo advice to t the availabl ness of bron tment of sev ce in the clin resulting un y of consid this applicat pite treatme maximal inha ong-acting b ng the delive single use c er moderate ocedures w ation for the ose asthma s required tha lic Sum – Bronc severe p Bos ion: MS makes its ad tion and l sting Medic persistent a ber

2015 Medical Services Advisory Committee

3. Bronchial thermoplasty for moderate or severe persistent asthma in adults. (PubMed)

Bronchial thermoplasty for moderate or severe persistent asthma in adults. Bronchial thermoplasty is a procedure that consists of the delivery of controlled radiofrequency-generated heat via a catheter inserted into the bronchial tree of the lungs through a flexible bronchoscope. It has been suggested that bronchial thermoplasty works by reducing airway smooth muscle, thereby reducing the ability of the smooth muscle to bronchoconstrict. This treatment could then reduce asthma symptoms (...) and exacerbations, resulting in improved asthma control and quality of life.To determine the efficacy and safety of bronchial thermoplasty in adults with bronchial asthma.We searched the Cochrane Airways Group Specialised Register of Trials (CAGR) up to January 2014.We included randomised controlled clinical trials that compared bronchial thermoplasty versus any active control in adults with moderate or severe persistent asthma. Our primary outcomes were quality of life, asthma exacerbations and adverse

Full Text available with Trip Pro

2014 Cochrane

4. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation

Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation

2013 NIHR HTA programme

5. Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) (TA278)

Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) (TA278) Overview | Omalizumab for treating severe persistent allergic asthma | Guidance | NICE Omalizumab for treating severe persistent allergic asthma Technology appraisal guidance [TA278] Published date: 24 April 2013 Share Guidance on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over. This guidance replaces NICE technology appraisal (...) guidance on omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201) and omalizumab for severe persistent asthma (TA133). Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

6. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma (PubMed)

Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma The severity of asthma (SOA) score is based on a validated disease-specific questionnaire that addresses frequency of asthma symptoms, use of systemic corticosteroids, use of other asthma medications, and history of hospitalization/intubation for asthma. SOA does not require measurements of pulmonary function. This study compared the ability of SOA to predict clinical outcomes in the EXCELS (...) (Epidemiological Study of Xolair [omalizumab]: Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate to Severe Asthma) patient population vs three other asthma assessment tools. EXCELS is a large, ongoing, observational study of patients with moderate to severe persistent asthma and reactivity to perennial aeroallergens.Baseline scores for SOA, asthma control test (ACT), work productivity and impairment index-asthma (WPAI-A), and FEV(1) % predicted were compared for their ability

2012 EvidenceUpdates

7. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years National Institute for Health and Clinical Excellence Citation National Institute for Health and Clinical Excellence. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 (...) years. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 201. 2010 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Allergic Agents; Antibodies, Monoclonal; Asthma; Childs Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, UK

2010 Health Technology Assessment (HTA) Database.

8. Omalizumab for the treatment of severe persistent allergic asthma

Omalizumab for the treatment of severe persistent allergic asthma Omalizumab for the treatment of severe persistent allergic asthma Omalizumab for the treatment of severe persistent allergic asthma Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jones J, Shepherd J (...) , Hartwell D, Harris P, Cooper K, Takeda A, Davidson P. Omalizumab for the treatment of severe persistent allergic asthma. Health Technology Assessment 2009; 13(Suppl 2 Article 5): 31-39 Final publication URL Additional data URL Indexing Status Subject indexing assigned by NLM MeSH Anti-Asthmatic Agents /economics /therapeutic use; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Asthma /drug therapy; Cost-Benefit Analysiss; Omalizumab

Full Text available with Trip Pro

2009 Health Technology Assessment (HTA) Database.

9. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

10. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.